While the role of the CCL5/CCR5 axis in cancer has been a subject of conflicting reports (35), we found that CRCLM outgrowth increased in OVX mice treated with the CCR5 antagonist Mvc, suggesting a tumor-inhibitory role for CCL5 in this TME. This evidence concerns the gene CCL5 and cancer.